Javascript must be enabled to continue!
Abstract 1762: Phosphodiesterase 10, a novel target for colorectal cancer therapeutics
View through CrossRef
Abstract
Phosphodiesterase 10 (PDE10) is a newly characterized PDE isozyme that is expressed in regions of the brain affecting cognition and psychomotor activity. Inhibitors are currently being developed for the treatment of schizophrenia and Huntington's disease, one of which, Pf-2545920 (MP-10), is in clinical trials. Although PDE10 is not expressed in most peripheral tissues, we recently found high levels in colon tumor cells compared with normal colonocytes and that genetic silencing by siRNA selectively suppressed colon tumor cell growth. These observations suggest that PDE10 may represent a novel anticancer target. Pf-2545920 was found to selectively inhibit colon tumor cell growth. Here we show that PDE10 knockdown reduced the sensitivity of colon tumor cells to Pf-2545920. Consistent with the ability of PDE10 to degrade cGMP and cAMP, Pf-2545920 activated both PKG and PKA as determined using site-specific phospho-VASP antibodies. Treatment of colon tumor cells with Pf-2545920 induced caspase activation as well as cytotoxicity. A novel PDE10 inhibitor, MCI-030, was found to potently inhibit colon tumor cell lines with IC50 values in the 0.3μM range without significantly affecting the growth of normal colonocytes. MCI-030 appears to exhibit selectivity for cGMP PDE10 signaling over cAMP shown by the activation of PKG but not PKA at doses that match those which inhibit growth. PDE10 knockdown cells were appreciably less sensitive to MCI-030 as well. These findings support a novel role of PDE10 as a therapeutic target for the treatment or prevention of colorectal cancer.
Citation Format: Kevin J. Lee, Nan Li, Xi Chen, Bing Zhu, Larry Yet, Gary Piazza. Phosphodiesterase 10, a novel target for colorectal cancer therapeutics. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1762. doi:10.1158/1538-7445.AM2014-1762
American Association for Cancer Research (AACR)
Title: Abstract 1762: Phosphodiesterase 10, a novel target for colorectal cancer therapeutics
Description:
Abstract
Phosphodiesterase 10 (PDE10) is a newly characterized PDE isozyme that is expressed in regions of the brain affecting cognition and psychomotor activity.
Inhibitors are currently being developed for the treatment of schizophrenia and Huntington's disease, one of which, Pf-2545920 (MP-10), is in clinical trials.
Although PDE10 is not expressed in most peripheral tissues, we recently found high levels in colon tumor cells compared with normal colonocytes and that genetic silencing by siRNA selectively suppressed colon tumor cell growth.
These observations suggest that PDE10 may represent a novel anticancer target.
Pf-2545920 was found to selectively inhibit colon tumor cell growth.
Here we show that PDE10 knockdown reduced the sensitivity of colon tumor cells to Pf-2545920.
Consistent with the ability of PDE10 to degrade cGMP and cAMP, Pf-2545920 activated both PKG and PKA as determined using site-specific phospho-VASP antibodies.
Treatment of colon tumor cells with Pf-2545920 induced caspase activation as well as cytotoxicity.
A novel PDE10 inhibitor, MCI-030, was found to potently inhibit colon tumor cell lines with IC50 values in the 0.
3μM range without significantly affecting the growth of normal colonocytes.
MCI-030 appears to exhibit selectivity for cGMP PDE10 signaling over cAMP shown by the activation of PKG but not PKA at doses that match those which inhibit growth.
PDE10 knockdown cells were appreciably less sensitive to MCI-030 as well.
These findings support a novel role of PDE10 as a therapeutic target for the treatment or prevention of colorectal cancer.
Citation Format: Kevin J.
Lee, Nan Li, Xi Chen, Bing Zhu, Larry Yet, Gary Piazza.
Phosphodiesterase 10, a novel target for colorectal cancer therapeutics.
[abstract].
In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA.
Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1762.
doi:10.
1158/1538-7445.
AM2014-1762.
Related Results
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
Abstract
Background
Given the increasing prevalence of non-albicans Candida species, including C. glabrata and C. auris, which h...
Abstract A13: Applied the proteomics characteristics to detect the inherited colorectal adenomas
Abstract A13: Applied the proteomics characteristics to detect the inherited colorectal adenomas
Abstract
Introduction: Current study found that about one-third of the incidence of colorectal cancer have genetic related. Hereditary nonpolyposis colorectal cancer...
Abstract 5777: Functional role of PLK1 in colorectal cancer progression and its potential to chemoresistance
Abstract 5777: Functional role of PLK1 in colorectal cancer progression and its potential to chemoresistance
Abstract
OBJECTIVE:
Colorectal cancer is a cancer with high prevalence and mortality rates worldwide, treated with surger...
The prevention of colorectal cancer
The prevention of colorectal cancer
Colorectal cancer is a leading cause of cancer mortality in the industrialized world. Survival remains poor because most cases are diagnosed at an advanced stage. It is a preventab...
Abstract 6642: Inter-alpha-trypsin inhibitor heavy chain (ITIH) genes: expressional profile in colorectal cancer and potential targeting by using a ribosome inactivating protein
Abstract 6642: Inter-alpha-trypsin inhibitor heavy chain (ITIH) genes: expressional profile in colorectal cancer and potential targeting by using a ribosome inactivating protein
Abstract
Introduction:
Expression deregulation of Inter-α-Trypsin Inhibitor Heavy (ITIH) genes at circulatory and tissue levels ...

